Novartis AG (NYSE:NVS) major shareholder Bioventures Ltd Novartis sold 132,738 shares of the stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $2.12, for a total transaction of $281,404.56. The transaction was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Bioventures Ltd Novartis also recently made the following trade(s):
- On Friday, March 15th, Bioventures Ltd Novartis sold 43,800 shares of Novartis stock. The shares were sold at an average price of $1.92, for a total transaction of $84,096.00.
Shares of Novartis stock traded up $1.27 during trading on Friday, hitting $93.29. The stock had a trading volume of 2,656,247 shares, compared to its average volume of 1,949,830. The firm has a market capitalization of $212.57 billion, a PE ratio of 18.33, a price-to-earnings-growth ratio of 1.96 and a beta of 0.67. The company has a current ratio of 1.20, a quick ratio of 0.97 and a debt-to-equity ratio of 0.29. Novartis AG has a 12 month low of $72.30 and a 12 month high of $93.62.
The company also recently announced an annual dividend, which was paid on Wednesday, March 13th. Stockholders of record on Tuesday, March 5th were issued a $2.8646 dividend. This represents a dividend yield of 3.27%. The ex-dividend date was Monday, March 4th. This is a positive change from Novartis’s previous annual dividend of $2.33. Novartis’s dividend payout ratio (DPR) is 36.15%.
Several equities analysts have commented on NVS shares. Cowen upgraded shares of Novartis from a “market perform” rating to an “outperform” rating and set a $88.03 price objective for the company in a research report on Sunday, December 2nd. JPMorgan Chase & Co. reiterated a “sell” rating on shares of Novartis in a research report on Wednesday, January 16th. Zacks Investment Research upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $96.00 price objective for the company in a research report on Tuesday, December 18th. Barclays lowered shares of Novartis from an “equal weight” rating to a “sell” rating in a research report on Friday, December 7th. Finally, Credit Suisse Group lowered shares of Novartis to a “sell” rating in a research report on Thursday, December 20th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $90.94.
Several institutional investors have recently added to or reduced their stakes in the company. AlphaMark Advisors LLC purchased a new position in Novartis in the 4th quarter worth about $30,000. Laurel Wealth Advisors LLC purchased a new position in Novartis in the 4th quarter worth about $35,000. Executive Wealth Management LLC purchased a new position in Novartis in the 4th quarter worth about $36,000. Sonora Investment Management LLC increased its stake in Novartis by 93.9% in the 4th quarter. Sonora Investment Management LLC now owns 479 shares of the company’s stock worth $41,000 after buying an additional 232 shares during the period. Finally, Front Row Advisors LLC increased its stake in Novartis by 90.7% in the 4th quarter. Front Row Advisors LLC now owns 492 shares of the company’s stock worth $42,000 after buying an additional 234 shares during the period. Hedge funds and other institutional investors own 11.68% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Novartis AG (NVS) Major Shareholder Bioventures Ltd Novartis Sells 132,738 Shares” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://sportsperspectives.com/2019/03/15/novartis-ag-nvs-major-shareholder-bioventures-ltd-novartis-sells-132738-shares.html.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
See Also: What is a Derivative?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.